Skip to main content
Erschienen in: European Journal of Epidemiology 6/2009

01.06.2009 | Diabetes Mellitus

Unfavourable risk factors for type 2 diabetes mellitus are already apparent more than a decade before onset in a population-based study of older persons: from the Age, Gene/Environment Susceptibility—Reykjavik Study (AGES-Reykjavik)

verfasst von: Elin Olafsdottir, Thor Aspelund, Gunnar Sigurdsson, Bolli Thorsson, Rafn Benediktsson, Tamara B. Harris, Lenore J. Launer, Gudny Eiriksdottir, Vilmundur Gudnason

Erschienen in: European Journal of Epidemiology | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

We evaluated midlife risk factors of developing type 2 diabetes mellitus (T2DM) in late life in a population-based study of older persons. A cohort of 2,251 persons, aged 65–96, participated in AGES-Reykjavik in 2002–2004; all attended the Reykjavik Study 26 years earlier, at the mean age of 50. Based on glucometabolic status in 2002–2004 the participants are divided into a normoglycemic control group (n = 1,695), an impaired fasting glucose (IFG) group (n = 313) and T2DM group (n = 243). Change in risk parameters from midlife is evaluated retrospectively in these three groups. Since examined earlier 14.3% of men and 8.2% of women developed T2DM. A family history of diabetes was reported in 39.5% of T2DM compared to 19.3% in both IFG and normoglycemics. The T2DM and IFG groups currently have higher levels of fasting triglycerides, greater body mass index (BMI) and higher systolic blood pressure than normoglycemics and this difference was already apparent in midlife. In late life, two or more metabolic syndrome criteria are present in 60% of the T2DM groups compared to 25% in normoglycemic groups. T2DM with impaired cardiovascular health is more marked in women than men when compared with normoglycemics. Family history and higher levels of BMI, triglycerides and systolic blood pressure in midlife are associated with the development of T2DM in late life, suggesting risk can be evaluated long before onset. A continued rise in risk factors throughout life allows for more aggressive measures in preventing or delaying development of T2DM and its effect on cardiovascular health.
Literatur
2.
Zurück zum Zitat McCarthy MI. Progress in defining the molecular basis of type 2 diabetes mellitus through susceptibility-gene identification. Hum Mol Genet. 2004;13(Spec No 1):R33–41.PubMedCrossRef McCarthy MI. Progress in defining the molecular basis of type 2 diabetes mellitus through susceptibility-gene identification. Hum Mol Genet. 2004;13(Spec No 1):R33–41.PubMedCrossRef
3.
Zurück zum Zitat Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50. doi:10.1056/NEJM200105033441801.PubMedCrossRef Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50. doi:10.​1056/​NEJM200105033441​801.PubMedCrossRef
4.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. doi:10.1056/NEJMoa012512.PubMedCrossRef Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. doi:10.​1056/​NEJMoa012512.PubMedCrossRef
8.
Zurück zum Zitat Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMed Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMed
9.
10.
Zurück zum Zitat Dehghan A, van Hoek M, Sijbrands EJ, Stijnen T, Hofman A, Witteman JC. Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care. 2007;30:2695–9. doi:10.2337/dc07-0348.PubMedCrossRef Dehghan A, van Hoek M, Sijbrands EJ, Stijnen T, Hofman A, Witteman JC. Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care. 2007;30:2695–9. doi:10.​2337/​dc07-0348.PubMedCrossRef
12.
Zurück zum Zitat Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol. 2007;165:1076–87. doi:10.1093/aje/kwk115.PubMedCrossRef Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol. 2007;165:1076–87. doi:10.​1093/​aje/​kwk115.PubMedCrossRef
13.
Zurück zum Zitat Jonsdottir LS, Sigfusson N, Gudnason V, Sigvaldason H, Thorgeirsson G. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk. 2002;9:67–76. doi:10.1097/00043798-200204000-00001.PubMedCrossRef Jonsdottir LS, Sigfusson N, Gudnason V, Sigvaldason H, Thorgeirsson G. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk. 2002;9:67–76. doi:10.​1097/​00043798-200204000-00001.PubMedCrossRef
14.
Zurück zum Zitat World Health Organization. Expert Committee Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999. World Health Organization. Expert Committee Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.
15.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9. doi:10.1007/BF00280883.PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9. doi:10.​1007/​BF00280883.PubMedCrossRef
16.
Zurück zum Zitat Rose GA, Blackburn H. Cardiovascular survey methods. Geneva: World Health Organization; 1968. Rose GA, Blackburn H. Cardiovascular survey methods. Geneva: World Health Organization; 1968.
18.
Zurück zum Zitat Rifai N, Warnick GR, Dominiczak M, editors. Handbook of lipoprotein testing. 1st ed. Washington DC: AACC Press; 1997. Rifai N, Warnick GR, Dominiczak M, editors. Handbook of lipoprotein testing. 1st ed. Washington DC: AACC Press; 1997.
19.
Zurück zum Zitat Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998;21:518–24. doi:10.2337/diacare.21.4.518.PubMedCrossRef Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998;21:518–24. doi:10.​2337/​diacare.​21.​4.​518.PubMedCrossRef
21.
Zurück zum Zitat Bjornsdottir S, Rossberger J, Gudbjornsdottir HS, Hreidarsson AB. Treatment pattern and results in an outpatient population with type 2 diabetes in Iceland. Laeknabladid. 2004;90:623–7. Bjornsdottir S, Rossberger J, Gudbjornsdottir HS, Hreidarsson AB. Treatment pattern and results in an outpatient population with type 2 diabetes in Iceland. Laeknabladid. 2004;90:623–7.
24.
Zurück zum Zitat Bergsveinsson J, Aspelund T, Gudnason V, Benediktsson R. Prevalence of type 2 diabetes mellitus in Iceland 1967–2002. Laeknabladid. 2007;93:397–402.PubMed Bergsveinsson J, Aspelund T, Gudnason V, Benediktsson R. Prevalence of type 2 diabetes mellitus in Iceland 1967–2002. Laeknabladid. 2007;93:397–402.PubMed
26.
Zurück zum Zitat Eiriksdottir G, Smith AV, Aspelund T, Hafsteinsdottir SH, Olafsdottir E, Launer LJ, et al. The interaction of adiposity with the CRP gene affects CRP levels: age, gene/environment susceptibility-Reykjavik study. Int J Obes Lond. 2009;33:267–72. doi:10.1038/ijo.2008.274.PubMedCrossRef Eiriksdottir G, Smith AV, Aspelund T, Hafsteinsdottir SH, Olafsdottir E, Launer LJ, et al. The interaction of adiposity with the CRP gene affects CRP levels: age, gene/environment susceptibility-Reykjavik study. Int J Obes Lond. 2009;33:267–72. doi:10.​1038/​ijo.​2008.​274.PubMedCrossRef
Metadaten
Titel
Unfavourable risk factors for type 2 diabetes mellitus are already apparent more than a decade before onset in a population-based study of older persons: from the Age, Gene/Environment Susceptibility—Reykjavik Study (AGES-Reykjavik)
verfasst von
Elin Olafsdottir
Thor Aspelund
Gunnar Sigurdsson
Bolli Thorsson
Rafn Benediktsson
Tamara B. Harris
Lenore J. Launer
Gudny Eiriksdottir
Vilmundur Gudnason
Publikationsdatum
01.06.2009
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe 6/2009
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-009-9343-x

Weitere Artikel der Ausgabe 6/2009

European Journal of Epidemiology 6/2009 Zur Ausgabe